Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (14794) 14794
Publication (1167) 1167
Book Review (67) 67
Book Chapter (64) 64
Dissertation (54) 54
Conference Proceeding (41) 41
Newsletter (15) 15
Government Document (7) 7
Book / eBook (5) 5
Magazine Article (5) 5
Web Resource (5) 5
Data Set (3) 3
Streaming Video (2) 2
Journal / eJournal (1) 1
Newspaper Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10612) 10612
camptothecin - analogs & derivatives (8424) 8424
oncology (5298) 5298
index medicus (5095) 5095
camptothecin - administration & dosage (4943) 4943
camptothecin (4833) 4833
female (4796) 4796
male (4469) 4469
camptothecin - pharmacology (3670) 3670
antineoplastic combined chemotherapy protocols - therapeutic use (3620) 3620
middle aged (3521) 3521
animals (3347) 3347
aged (3302) 3302
irinotecan (3167) 3167
cancer (2878) 2878
chemotherapy (2780) 2780
adult (2713) 2713
camptothecin - therapeutic use (2369) 2369
pharmacology & pharmacy (2222) 2222
colorectal neoplasms - drug therapy (2143) 2143
mice (1916) 1916
treatment outcome (1890) 1890
fluorouracil - administration & dosage (1783) 1783
camptothecin - adverse effects (1753) 1753
cell line, tumor (1653) 1653
apoptosis (1406) 1406
colorectal neoplasms - pathology (1394) 1394
biochemistry & molecular biology (1353) 1353
antineoplastic combined chemotherapy protocols - adverse effects (1344) 1344
colorectal cancer (1336) 1336
topoisomerase i inhibitors (1332) 1332
antineoplastic agents - pharmacology (1310) 1310
leucovorin - administration & dosage (1209) 1209
camptothecin - pharmacokinetics (1178) 1178
cpt-11 (1169) 1169
organoplatinum compounds - administration & dosage (1143) 1143
antineoplastic agents, phytogenic - pharmacology (1107) 1107
drug administration schedule (1093) 1093
antineoplastic agents, phytogenic - administration & dosage (1078) 1078
dose-response relationship, drug (1078) 1078
antineoplastic combined chemotherapy protocols - administration & dosage (1060) 1060
apoptosis - drug effects (1049) 1049
camptothecin - chemistry (1041) 1041
antineoplastic agents - therapeutic use (998) 998
fluorouracil (986) 986
dna topoisomerases, type i - metabolism (941) 941
antineoplastic agents, phytogenic - therapeutic use (921) 921
analysis (911) 911
lung neoplasms - drug therapy (908) 908
oxaliplatin (882) 882
research (868) 868
tumor cells, cultured (857) 857
aged, 80 and over (848) 848
topotecan (838) 838
neoplasms - drug therapy (832) 832
care and treatment (817) 817
disease-free survival (814) 814
dna damage (810) 810
cisplatin - administration & dosage (806) 806
topoisomerase-i (797) 797
adenocarcinoma - drug therapy (774) 774
tumors (772) 772
survival rate (770) 770
bevacizumab (768) 768
drugs (763) 763
antineoplastic agents - administration & dosage (760) 760
therapy (755) 755
leucovorin (750) 750
expression (747) 747
enzyme inhibitors - pharmacology (746) 746
antitumor-activity (744) 744
deoxycytidine - analogs & derivatives (738) 738
fluorouracil - therapeutic use (735) 735
cisplatin (730) 730
cell survival - drug effects (727) 727
liver neoplasms - secondary (722) 722
neoplasm staging (720) 720
antineoplastic agents (719) 719
pharmacokinetics (713) 713
cell biology (707) 707
metastasis (696) 696
neoplasm metastasis (680) 680
chemistry, medicinal (674) 674
phase-ii (671) 671
chemistry, multidisciplinary (666) 666
medicine & public health (663) 663
cells (662) 662
dna (656) 656
5-fluorouracil (649) 649
trial (646) 646
article (634) 634
carcinoma (617) 617
liver neoplasms - drug therapy (614) 614
retrospective studies (613) 613
cytotoxicity (611) 611
drug delivery systems (611) 611
antimitotic agents (610) 610
rats (610) 610
mice, nude (605) 605
combination (602) 602
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13638) 13638
Japanese (774) 774
Chinese (270) 270
French (110) 110
German (50) 50
Italian (29) 29
Russian (22) 22
Hungarian (14) 14
Spanish (14) 14
Korean (12) 12
Portuguese (5) 5
Czech (4) 4
Dutch (3) 3
Lithuanian (3) 3
Polish (3) 3
Swedish (2) 2
Danish (1) 1
Norwegian (1) 1
Romanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
by Alberto F. Sobrero and Joan Maurel and Louis Fehrenbacher and Werner Scheithauer and Yousif A. Abubakr and Manfred P. Lutz and M. Eugenia Vega-Villegas and Cathy Eng and Ernst U. Steinhauer and Jana Prausova and Heinz-Josef Lenz and Christophe Borg and Gary Middleton and Hendrik Kröning and Gabriele Luppi and Oliver Kisker and Angela Zubel and Christiane Langer and Justin Kopit and Howard A. Burris III
Journal of Clinical Oncology, ISSN 0732-183X, 05/2008, Volume 26, Issue 14, pp. 2311 - 2319
Purpose To determine whether adding cetuximab to irinotecan prolongs survival in patients with metastatic colorectal cancer (mCRC) previously treated with... 
SURVIVAL | 1ST-LINE TREATMENT | SUPPORTIVE CARE | LEUCOVORIN | MULTICENTER | MUTATION STATUS | ONCOLOGY | FLUOROURACIL FAILURE | RANDOMIZED-TRIAL | FOLFIRI | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antibodies, Monoclonal, Humanized | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Cetuximab | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Receptor, Epidermal Growth Factor - biosynthesis | Camptothecin - therapeutic use | Pyrimidines - administration & dosage | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Quality of Life | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - adverse effects | Index Medicus | Camptothecin | Organoplatinum Compounds | Antineoplastic Combined Chemotherapy Protocols | Antibodies, Monoclonal | Life Sciences | Pyrimidines | Immunology | Colorectal Neoplasms | Receptor, Epidermal Growth Factor
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies
by Weiss, Glen J and Chao, Joseph and Neidhart, Jeffrey D and Ramanathan, Ramesh K and Bassett, Dawn and Neidhart, James A and Choi, Chung Hang J and Chow, Warren and Chung, Vincent and Forman, Stephen J and Garmey, Edward and Hwang, Jungyeon and Kalinoski, D Lynn and Koczywas, Marianna and Longmate, Jeffrey and Melton, Roger J and Morgan, Robert and Oliver, Jamie and Peterkin, Joanna J and Ryan, John L and Schluep, Thomas and Synold, Timothy W and Twardowski, Przemyslaw and Davis, Mark E and Yen, Yun
Investigational New Drugs, ISSN 0167-6997, 8/2013, Volume 31, Issue 4, pp. 986 - 1000
Patients with advanced solid malignancies were enrolled to an open-label, single-arm, dose-escalation study, in which CRLX101 was administered intravenously... 
Phase 1/2a | Solid tumor | Medicine & Public Health | Nanopharmaceutical | Oncology | Polymer conjugate camptothecin | Pharmacology/Toxicology | CONJUGATE IT-101 | MECHANISM | CANCER-CELL-LINES | OVARIAN-CANCER | CHEMOTHERAPY | PHARMACOKINETICS | ONCOLOGY | TOPOTECAN | PHARMACOLOGY & PHARMACY | INHIBITORS | NSC-100880 | Cellulose - blood | Immunohistochemistry | Cyclodextrins - adverse effects | Demography | Cellulose - therapeutic use | Area Under Curve | Humans | Middle Aged | Male | Tomography, X-Ray Computed | Nanoparticles - adverse effects | Cyclodextrins - therapeutic use | Dose-Response Relationship, Drug | Nanoparticles - therapeutic use | Camptothecin - blood | Cellulose - pharmacokinetics | Adult | Female | Cellulose - adverse effects | Camptothecin - pharmacokinetics | Camptothecin - adverse effects | Camptothecin - therapeutic use | Cyclodextrins - pharmacokinetics | Treatment Outcome | Neoplasms - diagnostic imaging | Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Cyclodextrins - blood | Biopsy | Aged | Neoplasm Staging | Neoplasms - pathology | Camptothecin | Complications and side effects | Dosage and administration | Drug therapy | Tumors | Studies | Research | Cancer therapies | Pharmaceutical sciences | Index Medicus | Phase 1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Transformative Nanomedicine of an Amphiphilic Camptothecin Prodrug for Long Circulation and High Tumor Uptake in Cancer Therapy
by Zhang, Fuwu and Zhu, Guizhi and Jacobson, Orit and Liu, Yi and Chen, Kai and Yu, Guocan and Ni, Qianqian and Fan, Jing and Yang, Zhen and Xu, Frederick and Fu, Xiao and Wang, Zhe and Ma, Ying and Niu, Gang and Zhao, Xiaobin and Chen, Xiaoyuan
ACS Nano, ISSN 1936-0851, 09/2017, Volume 11, Issue 9, pp. 8838 - 8848
We report a camptothecin (CPT) prodrug that was well formulated in solution and rapidly transformed into long-circulating nanocomplexes in vivo for highly... 
self-assembly | camptothecin prodrug | drug delivery | nanostructures | albumin | DRUG-DELIVERY | STATISTICS | SERUM-ALBUMIN | STABILITY | MATERIALS SCIENCE, MULTIDISCIPLINARY | CHEMISTRY, PHYSICAL | NANOSCIENCE & NANOTECHNOLOGY | COMBINATION | CHEMISTRY, MULTIDISCIPLINARY | CHEMOTHERAPY | MACROMOLECULAR THERAPEUTICS | NANOPARTICLES | CONJUGATE | Prodrugs - administration & dosage | Camptothecin - chemistry | Nanoparticles - chemistry | Humans | Surface-Active Agents - pharmacokinetics | Prodrugs - chemistry | Drug Delivery Systems | Antineoplastic Agents, Phytogenic - administration & dosage | Camptothecin - blood | Camptothecin - administration & dosage | Female | Antineoplastic Agents, Phytogenic - pharmacokinetics | Antineoplastic Agents, Phytogenic - blood | Camptothecin - pharmacokinetics | Oxidation-Reduction | HCT116 Cells | Solubility | Antineoplastic Agents, Phytogenic - chemistry | Nanoconjugates - administration & dosage | Neoplasms - drug therapy | Animals | Prodrugs - pharmacokinetics | Mice, Nude | Mice | Surface-Active Agents - chemistry | Nanoconjugates - chemistry | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Chemotherapy for advanced gastric cancer
by Wagner, Anna Dorothea and Syn, Nicholas L.X and Moehler, Markus and Grothe, Wilfried and Yong, Wei Peng and Tai, Bee-Choo and Ho, Jingshan and Unverzagt, Susanne
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 08/2017, Volume 2017, Issue 8, pp. CD004064 - CD004064
Background Gastric cancer is the fifth most common cancer worldwide. In "Western" countries, most people are either diagnosed at an advanced stage, or develop... 
1ST-LINE TREATMENT | OLDER-ADULT PATIENTS | COLONY-STIMULATING FACTOR | Humans | Anthracyclines [administration & dosage] | Cisplatin [administration & dosage] | HIGH-DOSE 5-FLUOROURACIL | Fluorouracil [administration & dosage] | Randomized Controlled Trials as Topic | MEDICINE, GENERAL & INTERNAL | analogs & derivatives | RANDOMIZED PHASE-II | ADVANCED GASTROINTESTINAL CANCER | mortality | Taxoids [administration & dosage] | Antineoplastic Combined Chemotherapy Protocols [therapeutic use] | QUALITY-OF-LIFE | GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA | Camptothecin [administration & dosage | Stomach Neoplasms [drug therapy | S-1 PLUS CISPLATIN | COOPERATIVE-ONCOLOGY-GROUP | Docetaxel | Stomach Neoplasms - drug therapy | Cisplatin - administration & dosage | Irinotecan | Taxoids - administration & dosage | Anthracyclines - administration & dosage | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Camptothecin - administration & dosage | Stomach Neoplasms - mortality | Camptothecin - analogs & derivatives | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers
by Zhao, Hong and Rubio, Belen and Sapra, Puja and Wu, Dechun and Reddy, Prasanna and Sai, Prakash and Martinez, Anthony and Gao, Ying and Lozanguiez, Yoany and Longley, Clifford and Greenberger, Lee M and Horak, Ivan D
Bioconjugate Chemistry, ISSN 1043-1802, 04/2008, Volume 19, Issue 4, pp. 849 - 859
CPT-11, also known as irinotecan, is a prodrug that is approved for the treatment of advanced colorectal cancer. The active metabolite of CPT-11, SN38... 
ACTIVATION | CPT-11 | BIOCHEMISTRY & MOLECULAR BIOLOGY | BIOCHEMICAL RESEARCH METHODS | CHEMISTRY, ORGANIC | CARBOXYLESTERASES | CLINICAL PHARMACOKINETICS | IDENTIFICATION | CHEMISTRY, MULTIDISCIPLINARY | CONJUGATION | TRANSPORT | METABOLISM | CAMPTOTHECIN | DRUG-DELIVERY SYSTEMS | Camptothecin - metabolism | Temperature | Camptothecin - chemistry | Camptothecin - toxicity | Humans | Solubility | Polyethylene Glycols - chemistry | Prodrugs - chemistry | Antineoplastic Agents - chemistry | Prodrugs - metabolism | Antineoplastic Agents - toxicity | Antineoplastic Agents - metabolism | Maximum Tolerated Dose | Animals | Mice, Nude | Prodrugs - toxicity | Cell Line, Tumor | Female | Antineoplastic Agents - pharmacology | Mice | Camptothecin - pharmacology | Prodrugs - pharmacology | Camptothecin - analogs & derivatives | Hydrogen-Ion Concentration | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text The Role of Micelle Size in Tumor Accumulation, Penetration, and Treatment
by Wang, Jinqiang and Mao, Weiwei and Lock, Lye Lin and Tang, Jianbin and Sui, Meihua and Sun, Weilin and Cui, Honggang and Xu, Dong and Shen, Youqing
ACS Nano, ISSN 1936-0851, 07/2015, Volume 9, Issue 7, pp. 7195 - 7206
The specific sizes that determine optimal nanoparticle tumor accumulation, penetration, and treatment remain inconclusive because many studies compared... 
polymeric micelle | 7-ethyl-10-hydroxylcamptothecin | cancer drug delivery | tumor penetration | size effect | THERAPEUTICS | CREMOPHOR-FREE | MATERIALS SCIENCE, MULTIDISCIPLINARY | CHEMISTRY, PHYSICAL | PHASE-II | NANOSCIENCE & NANOTECHNOLOGY | BIODISTRIBUTION | CHEMISTRY, MULTIDISCIPLINARY | POLYMERIC NANOPARTICLES | MICROENVIRONMENT | PRODRUG | IN-VIVO | PARTICLE-SIZE | CANCER DRUG-DELIVERY | Camptothecin - pharmacokinetics | Camptothecin - therapeutic use | Humans | Mice, Inbred ICR | Antineoplastic Agents, Phytogenic - administration & dosage | Animals | Mice, Nude | Micelles | Cell Line, Tumor | Camptothecin - administration & dosage | Female | Mice | Mice, Inbred BALB C | Antineoplastic Agents, Phytogenic - therapeutic use | Antineoplastic Agents, Phytogenic - pharmacokinetics | Camptothecin - analogs & derivatives | Mammary Neoplasms, Experimental - drug therapy | Drugs | Penetration | Effectiveness | Nanostructure | Physical properties | Optimization | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics
by Ocean, Allyson J and Starodub, Alexander N and Bardia, Aditya and Vahdat, Linda T and Isakoff, Steven J and Guarino, Michael and Messersmith, Wells A and Picozzi, Vincent J and Mayer, Ingrid A and Wegener, William A and Maliakal, Pius and Govindan, Serengulam V and Sharkey, Robert M and Goldenberg, David M
Cancer, ISSN 0008-543X, 10/2017, Volume 123, Issue 19, pp. 3843 - 3854
Sacituzumab govitecan (IMMU‐132), an antibody‐drug conjugate targeting SN‐38 to Trop‐2 (an antigen identified in many epithelial cancers), is exhibiting... 
clinical trial | trophoblastic cell‐surface antigen (Trop‐2) | epithelial cancers | antibody‐drug conjugate | IMMU‐132 (sacituzumab govitecan) | SN‐38 | trophoblastic cell-surface antigen (Trop-2) | SN-38 | antibody-drug conjugate | IMMU-132 (sacituzumab govitecan) | METABOLITES | SOLID TUMORS | ETIRINOTECAN PEGOL NKTR-102 | CLINICAL PHARMACOKINETICS | BREAST-CANCER | EZN-2208 | ONCOLOGY | COLORECTAL-CANCER | THERAPEUTIC TARGET | IRINOTECAN | trophoblastic cellsurface antigen (Trop-2) | Neoplasms - metabolism | Humans | Middle Aged | Half-Life | Immunoconjugates - pharmacokinetics | Male | Response Evaluation Criteria in Solid Tumors | Immunoconjugates - administration & dosage | Glucuronosyltransferase - genetics | Antineoplastic Agents, Phytogenic - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Antibodies, Monoclonal, Humanized - pharmacokinetics | Camptothecin - blood | Aged, 80 and over | Antigens, Neoplasm - metabolism | Adult | Camptothecin - administration & dosage | Female | Neutropenia - chemically induced | Antineoplastic Agents, Phytogenic - pharmacokinetics | Antineoplastic Agents, Phytogenic - adverse effects | Camptothecin - analogs & derivatives | Immunoconjugates - adverse effects | Camptothecin - pharmacokinetics | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Cell Adhesion Molecules - metabolism | Neoplasms - drug therapy | Irinotecan | Aged | Immunoglobulin G - metabolism | Usage | Care and treatment | Safety and security measures | Analysis | Epithelial tumors | Pharmacokinetics | Antibody-drug conjugates | Camptothecin | Antigens | Toxicity | Immunoglobulin G | Radioactive half-life | Breast cancer | Pharmacology | Metastasis | Criteria | Patients | Cell surface | Metastases | Uridine | Safety | Solid tumors | Drug dosages | Cancer | Tumors | Half life | Neutropenia | Glucuronosyltransferase | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Engineering of a lipid-polymer nanoarchitectural platform for highly effective combination therapy of doxorubicin and irinotecan
by Ramasamy, T and Ruttala, H B and Choi, J Y and Tran, T H and Kim, J H and Ku, S K and Choi, H G and Yong, C S and Kim, J O
Chemical communications (Cambridge, England), ISSN 1359-7345, 04/2015, Volume 51, Issue 26, pp. 5758 - 5761
We developed a highly stable lipid-polymer nanoarchitectural platform for effective combination therapy of doxorubicin and irinotecan in the polyelectrolyte... 
Doxorubicin - therapeutic use | Camptothecin - chemistry | Nanoparticles - chemistry | Humans | Antineoplastic Agents - therapeutic use | Doxorubicin - chemistry | Structure-Activity Relationship | Antineoplastic Agents - administration & dosage | Lecithins - chemistry | MCF-7 Cells | Camptothecin - administration & dosage | Antineoplastic Agents - pharmacology | Camptothecin - analogs & derivatives | Doxorubicin - administration & dosage | Cell Line | Camptothecin - therapeutic use | Antineoplastic Agents - chemistry | Animals | Mice, Nude | Polymers - chemistry | Cell Proliferation - drug effects | Mice | HeLa Cells | Lipid Bilayers - chemistry | Camptothecin - pharmacology | Neoplasms, Experimental - drug therapy | Doxorubicin - pharmacology | Drug Combinations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Linear-dendritic drug conjugates forming long-circulating nanorods for cancer-drug delivery
by Zhou, Zhuxian and Ma, Xinpeng and Jin, Erlei and Tang, Jianbin and Sui, Meihua and Shen, Youqing and Van Kirk, Edward A and Murdoch, William J and Radosz, Maciej
Biomaterials, ISSN 0142-9612, 2013, Volume 34, Issue 22, pp. 5722 - 5735
Abstract Elongated micelles have many desirable characteristics for cancer-drug delivery, but they are difficult to obtain since amphiphilic polymers form such... 
Advanced Basic Science | Dentistry | Cancer-drug delivery | Linear-dendritic polymer | Camptothecin | Self-assembly | Drug conjugate | Nanorods | DESIGN | MATERIALS SCIENCE, BIOMATERIALS | ENGINEERING, BIOMEDICAL | NANOMATERIALS | BIODISTRIBUTION | RELEASE | POLYMERIC MICELLES | CARRIERS | CHALLENGES | NANOPARTICLES | SHAPE | BLOOD-CELLS | Neoplasms - metabolism | Doxorubicin - therapeutic use | Camptothecin - chemistry | Humans | Polyethylene Glycols - chemistry | Polylysine - chemistry | Chromatography, High Pressure Liquid | Drug Carriers - chemistry | Drug Delivery Systems | Nanotubes - chemistry | MCF-7 Cells | Time Factors | Micelles | Camptothecin - administration & dosage | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | Cell Death - drug effects | Camptothecin - pharmacokinetics | Nanotubes - ultrastructure | Tissue Distribution - drug effects | Magnetic Resonance Spectroscopy | Drug Stability | Endocytosis - drug effects | Neoplasms - drug therapy | Diagnostic Imaging | Animals | Polylysine - chemical synthesis | Mice | Mice, Inbred BALB C | Polyethylene Glycols - chemical synthesis | Camptothecin - pharmacology | Doxorubicin - pharmacology | Drugs | Care and treatment | Drug delivery systems | Drug therapy | Polymers | Cancer | Vehicles | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text DNA topoisomerase I Inhibitors: Chemistry, biology, and interfacial inhibition
by Pommier, Yves
Chemical Reviews, ISSN 0009-2665, 07/2009, Volume 109, Issue 7, pp. 2894 - 2902
RING-MODIFIED CAMPTOTHECIN | SPINOCEREBELLAR ATAXIA | ANTICANCER ALKALOID CAMPTOTHECIN | CLEAVAGE COMPLEXES | NITRATED INDENOISOQUINOLINES | DOUBLE-STRAND BREAKS | PHOSPHODIESTERASE TDP1 | ANTITUMOR-ACTIVITY | CELL-LINES | CHEMISTRY, MULTIDISCIPLINARY | COVALENT COMPLEXES | Camptothecin - chemistry | DNA Topoisomerases, Type I - metabolism | DNA Repair | Enzyme Inhibitors - chemistry | Humans | DNA Topoisomerases, Type I - chemistry | Enzyme Inhibitors - pharmacology | Topoisomerase I Inhibitors | Neoplasms - enzymology | DNA Damage | Camptothecin - pharmacology | Chemical inhibitors | Chemical properties | Research | DNA damage | Oncology, Experimental | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors
by Koizumi, Fumiaki and Kitagawa, Masayuki and Negishi, Takahito and Onda, Takeshi and Matsumoto, Shin-Ichi and Hamaguchi, Tetsuya and Matsumura, Yasuhiro
Cancer Research, ISSN 0008-5472, 10/2006, Volume 66, Issue 20, pp. 10048 - 10056
7-Ethyl-10-hydroxy-camptothecin (SN-38), a biological active metabolite of irinotecan hydrochloride (CPT-11), has potent antitumor activity but has not been... 
LUNG-CANCER | SOLID TUMORS | ONCOLOGY | CAMPTOTHECIN | ACID) BLOCK-COPOLYMER | ANTICANCER DRUG | IRINOTECAN | ANTITUMOR-ACTIVITY | I CLINICAL-TRIAL | PHASE-I | METASTATIC COLORECTAL-CANCER | Lung Neoplasms - drug therapy | Camptothecin - chemistry | Nanoparticles - chemistry | Colonic Neoplasms - drug therapy | Lung Neoplasms - metabolism | Polyethylene Glycols - chemistry | Polyglutamic Acid - administration & dosage | Carcinoma, Non-Small-Cell Lung - secretion | Colonic Neoplasms - metabolism | Vascular Endothelial Growth Factor A - secretion | Tissue Distribution | Polyglutamic Acid - pharmacokinetics | Micelles | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Camptothecin - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - metabolism | Polyethylene Glycols - pharmacokinetics | Random Allocation | Polyethylene Glycols - administration & dosage | Xenograft Model Antitumor Assays | Lung Neoplasms - secretion | Polyglutamic Acid - chemistry | Animals | Colonic Neoplasms - blood | Carcinoma, Non-Small-Cell Lung - blood | Lung Neoplasms - blood | Mice | Mice, Inbred BALB C | Nanoparticles - administration & dosage | Carcinoma, Non-Small-Cell Lung - drug therapy | Camptothecin - pharmacology | Colonic Neoplasms - secretion
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights